Connect Biopharma Holdings (CNTB) Cash from Investing Activities (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Cash from Investing Activities for 3 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.

• Quarterly Cash from Investing Activities rose 129.07% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.5 million (up 209.35% YoY) and the FY2025 annual result came in at $9.8 million, up 384.5% from the prior year.
• Cash from Investing Activities fell to $6.0 million in Q1 2026 per CNTB's latest filing, from $11.0 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for CNTB reached as high as $14.3 million in Q3 2025 and fell as low as -$20.6 million in Q1 2025.
• A 3-year average of $1.4 million and a median of $5.1 million in 2025 frame the typical range for Cash from Investing Activities.
• The largest YoY upside for Cash from Investing Activities was 9859.18% in 2025 against a maximum downside of 323.15% in 2025.
• Year by year, Cash from Investing Activities stood at -$15.8 million in 2024, then surged by 169.68% to $11.0 million in 2025, then tumbled by 45.38% to $6.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $6.0 million, $11.0 million, and $14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.